BR9807365A - Composição para destruir células epiteliais de pigmento retinal e células proliferativas - Google Patents

Composição para destruir células epiteliais de pigmento retinal e células proliferativas

Info

Publication number
BR9807365A
BR9807365A BR9807365-6A BR9807365A BR9807365A BR 9807365 A BR9807365 A BR 9807365A BR 9807365 A BR9807365 A BR 9807365A BR 9807365 A BR9807365 A BR 9807365A
Authority
BR
Brazil
Prior art keywords
epithelial cells
cells
vitreous chamber
retinal pigment
pigment epithelial
Prior art date
Application number
BR9807365-6A
Other languages
English (en)
Inventor
Randolph H Bretton
Original Assignee
Bausch & Lomb Surgical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bausch & Lomb Surgical Inc filed Critical Bausch & Lomb Surgical Inc
Publication of BR9807365A publication Critical patent/BR9807365A/pt

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"COMPOSIçãO PARA DESTRUIR CéLULAS EPITELIAIS DE PIGMENTO RETINAL E CéLULAS PROLIFERATIVAS". Um método para destruir células epiteliais de pigmento retinal em um olho para evitar a ocorrência de vitreoretinopatia proliferativa. Uma solução contendo um agente ligante de membrana base conjugado a um agente citotóxico é introduzido na câmara vítrea. A solução é mantida na câmara vítrea por um período de tempo suficiente par permitir o agente ligante de membrana base se ligar a membranas base revestindo a câmara vítrea. A solução é então removida da câmara vítrea, através do que uma porção do agente ligante de membrana base permanece ligado a membranas base dentro da câmara vítrea, deste modo expondo células epiteliais de pigmento retinal dispostas na membrana base ao agente citotóxico.
BR9807365-6A 1997-02-13 1998-01-28 Composição para destruir células epiteliais de pigmento retinal e células proliferativas BR9807365A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3799497P 1997-02-13 1997-02-13
PCT/US1998/001408 WO1998035688A1 (en) 1997-02-13 1998-01-28 Method for destroying retinal pigment epithelial cells

Publications (1)

Publication Number Publication Date
BR9807365A true BR9807365A (pt) 2002-02-05

Family

ID=21897499

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9807365-6A BR9807365A (pt) 1997-02-13 1998-01-28 Composição para destruir células epiteliais de pigmento retinal e células proliferativas

Country Status (8)

Country Link
US (1) US6138680A (pt)
EP (1) EP1027065A1 (pt)
JP (1) JP2002501483A (pt)
CN (1) CN1252001A (pt)
AU (1) AU723614B2 (pt)
BR (1) BR9807365A (pt)
CA (1) CA2281690A1 (pt)
WO (1) WO1998035688A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6106554A (en) * 1999-02-25 2000-08-22 Bausch & Lomb Surgical, Inc. Intraocular lens implants for the prevention of secondary cataracts
KR100398783B1 (ko) * 1999-06-15 2003-09-19 가부시키가이샤 엔.티.티.도코모 인접 기지국 정보 갱신 방법, 이동 통신 시스템, 이동국, 기지국 및 제어국
WO2000078359A2 (en) * 1999-06-21 2000-12-28 George Tuszynski Compositions for treating chemotherapy-resistant tumor cells
US6380161B1 (en) 1999-06-21 2002-04-30 Inkine Pharmaceutical Company, Inc. Compositions for treating chemotherapy-resistant tumor cells and targeted chemotherapy compositions
US6558419B1 (en) * 2001-11-08 2003-05-06 Bausch & Lomb Incorporated Intraocular lens
ES2726804T3 (es) * 2011-02-25 2019-10-09 Riken Método de producción de lámina de células epiteliales de pigmento retiniano

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4920104A (en) * 1988-05-16 1990-04-24 Medchem Products, Inc. Sodium hyaluronate composition

Also Published As

Publication number Publication date
US6138680A (en) 2000-10-31
JP2002501483A (ja) 2002-01-15
WO1998035688A1 (en) 1998-08-20
CN1252001A (zh) 2000-05-03
AU5930798A (en) 1998-09-08
AU723614B2 (en) 2000-08-31
CA2281690A1 (en) 1998-08-20
EP1027065A1 (en) 2000-08-16

Similar Documents

Publication Publication Date Title
ES2118677T3 (es) Una composicion que comprende un agente activo disuelto en un vehiculo formador de vidrio y un procedimiento para su preparacion.
ES2159591T3 (es) Composicion de liberacion controlada.
BR9811793A (pt) MacrÈmeros biodegradáveis para a liberação controlada de substâncias biologicamente ativas.
BR9813961A (pt) Metodo para remover sais biliares de um paciente, polimero de polidialilamina e seus sais, e seu uso.
BG101960A (en) Controlled release of myotic and mydriatic medicaments in the front occular chamber
BR9000418A (pt) Composicao de spray para cabelos e processo para a producao da mesma
BR9808282A (pt) Liberação controlada de produtos farmacêuticos na câmara anterior do olho
CO4370096A1 (es) Liberacion controlada de esteroides a partir de revestimientos de azucar
BRPI0111116B8 (pt) imitadores de trombopoietina
CO4410203A1 (es) Formulaciones de analogos de insulina
MX9605646A (es) Preparacion de nifedipino de liberacion prolongada.
KR880000088A (ko) 지속적인 방출 제제
ATE209918T1 (de) Transdermales estradiol/progestogen-pflaster und dessen herstellung
ES2164842T3 (es) Procedimiento para la preparacion de composiciones de microcapsulas.
ES2152556T3 (es) Composiciones que contienen derivados del acido hidroperoxieicosatetraenoico y procedimientos de utilizacion en el tratamiento de trastornos de la sequedad ocular.
KR970703133A (ko) 중합체 매트릭스 중의 활성제의 고용체 형태로서의 활성제 제제의 제조 방법 및 그에 의해 얻어진 활성제 제제(Process for Producing Active Agent Preparations in the Form of a Solid Solution of the Active Agent in a Polymer Matrix and Active Agent Preparations Obtained Thereby)
BR9713199A (pt) Péletes de desintegração rápida
BR9609033B1 (pt) composição e emulsão para a liberação controlada de uma substáncia.
ES2102860T3 (es) Tratamiento cosmetico de substratos.
BR9815811A (pt) Método cosmético para tratar cabelo colorido a fim de reduzir o desvanecimetno da cor
WO2000021549A8 (en) A method of inducing or enhancing chondrogenesis with extracellular matrix containing gdf-5
BR0107549A (pt) Composição de pró-perfume
AR003928A1 (es) Comprimido del liberacion controlada
ES2187720T3 (es) Procedimiento para la preparacion de composiciones de vitamina b12 de alta concentracion.
BR9807365A (pt) Composição para destruir células epiteliais de pigmento retinal e células proliferativas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 5A, 6A,7A,8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1887 DE 06/03/2007.